Top Markets
Coin of the day
Antisense Therapeutics Limited Antisense Therapeutics Limited

Antisense Therapeutics Limited

ANP
Ранг среди акций #33642
Antisense Therapeutics Limited, an Australian company headquartered in Toorak... Antisense Therapeutics Limited, an Australian company headquartered in Toorak and founded in 2000, specializes in the research and advancement of innovative antisense pharmaceutical drugs. Its primary pipeline asset, ATL1102, is an antisense inhibitor designed to target CD49d, which is currently in Phase II clinical trials for treating various inflammatory conditions such as multiple sclerosis, Duchenne Muscular Dystrophy, and asthma. Another promising therapeutic in their portfolio is ATL1103, a second-generation antisense drug that aims to block growth hormone receptor expression, thereby lowering insulin-like growth factor-I levels in the blood, and has completed Phase II clinical trials for conditions stemming from excessive growth hormone action.
Цена акции
$0.03702159
Последняя синхронизация: 2024-01-29
Рыночная капитализация
$7.21M
Изменение (1 день)
-3.08%
Изменение (1 год)
0.00%
Страна
AU
Торговля Antisense Therapeutics Limited (ANP)

Категория

Коэффициент P/B для Antisense Therapeutics Limited (ANP)
Коэффициент P/B на 2026 TTM: 0
Согласно последним финансовым отчетам и цене акций Antisense Therapeutics Limited, текущий коэффициент P/B (TTM) составляет 0. В конце 2026 он составлял 0.
История P/B для Antisense Therapeutics Limited с 2026 по 2026
Коэффициент P/B в конце каждого года
Год P/B Изменить
Недостаточно данных для указанных дат.
Коэффициент P/B для аналогичных компаний или конкурентов